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Purpose: The purpose of this study is to present our preliminary experience of the temporary endovascu-
lar bypass (TEB) technique using an Enterprise stent for recanalization of acute intracranial artery
(IA) occlusion. 
Materials and Methods: Patients treated by TEB were enrolled in this retrospective study from January
2009 to May 2010. All the procedures consist of temporary partial deployment and subsequent
retrieval of Enterprise stent, supplemented by intra-arterial infusion of urokinase (UK) and/or
tirofiban. According to the thrombolysis in cerebral infarction (TICI) classification, recanalization
was evaluated with initial and postprocedural angiography. Safety was evaluated related to the
procedure and clinical outcomes were assessed by National Institute of Health Stroke Scale (NIHSS)
score at discharge and modified Rankin scale (mRS) score at 3 months.
Results: Eleven patients (median NIHSS 12.8, mean age 61.6 years, male: female = 8:3) with acute IA
occlusion were treated with TEB. All the patients presented with TICI 0, and the occluded vessel was
the middle cerebral artery (n=7), the basilar artery (n=1), and the distal ICA occlusion (n = 3). IV
infusion of tissue plasminogen activator (tPA) was done in 4 patients and mechanical thrombolysis
with intra-arterial UK was performed in 9. Recanalization was achieved in 73% (8 patients; TICI ≥
2). There were no procedure-related complications except for two asymptomatic intracranial hem-
orrhages. Improvement (≥ 4 points on the NIHSS) and good outcome (mRS ≤2) after 90 days was
shown in six patients (55%). One patient died 6 days after procedure.
Conclusion: TEB may be a valuable treatment option in acute thromboembolic IA occlusion without
stent implantation. 
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Since the Prolyse in Acute Cerebral Thrombo-
embolism (PROACT) II trial presented the milestone of
intra-arterial thrombolysis (IAT), the Interventional
Management of Stroke Study (IMS) - II pilot study has
proven to be to the advantage of IAT, with a favorable
functional outcome [1, 2]. Along with the advance of
materials and device technologies, various mechanical
approaches have been introduced in the treatment of
acute ischemic stroke, such as the Merci mechanical
clot retriever (Concentric Medical) or Penumbra
(Penumbra Inc). Using this device showed better results
for recanalization than the PROACT II trial [3].
However, it is also true that almost 30% of the patients
show no response to the currently approved
thrombolytic therapy. Recently, several cases series
have reported an excellent outcome of recanalization
with stent implantation as a rescue therapy for
treatment of acute ischemic stroke [4-7]. However,
treatment -related issues always exist, which include
hemorrhagic complications related to stent implanta-
tion, concerns about in-stent thrombosis or stenosis,
and stent durability. 
The Enterprise stent is a self-expandable, retrievable
stent which is currently approved as humanitarian
device exemption by the US Food and Drug
Administration for use in stent-assisted coil emboliza-
tion of intracranial wide-neck aneurysm. Although in
an off-label practice, these vascular reconstructive
stents have been applied with “temporary endovascular
bypass (TEB)” technique, which is a revascularization
technique using self-expandable stent (SES) for acute
stroke refractory to conventional thrombolytic therapy,
and some case reports have been subsequently released
with a good clinical outcome and fewer complications
[8-11]. Also other comparable studies using the
Solitaire stent (eV3, Irvine, CA, USA) have shown a
remarkable recanalization rate and clinical outcome
without stent implantation [12-18].
Therefore, we present our preliminary experience of




The institutional review board approval approved our
study for a retrospective review of the device used in an
off-label application and written informed consent was
obtained from the patients’ next of kin. The cases of all
patients treated by TEB for acute stroke from January
2009 until May 2010 were retrospectively analyzed.
Clinical data were collected from our stroke database.
Inclusion criteria for TEB were as follows: 1) clinical
diagnosis of acute stroke by neurologist, 2) baseline
NIHSS score ≥ 8, except for isolated aphasia,
hemianopia, 3) exclusion of intracranial hemorrhage
(ICH) by CT or MRI, 4) conf irmation of vessel
occlusion by angiography, correlating to neurologic
deficit, 5) no clinical or laboratory contraindication for
IAT, 6) initiation of treatment within 6 hours of
symptom onset for hemispheric stroke and within 9
hours for vertebrobasilar stroke, 7) informed consent
by patients’ relatives. Exclusion criteria for this study
were 1) patients with stroke ≥ 80 years, and 2) patients
recanalized after stent implantation. The baseline study
consisted of a neurological and physical examination,
assessment of stroke severity by the NIHSS, routine
blood analysis and electrocardiogram (ECG).
Interventional Technique
The patient was moved into the angiographic suite
and diagnostic angiography was performed to evaluate
the occlusive segment of the intracranial arteries (IA)
and collateral flows. Under local anesthesia, a 6 Fr
Envoy guiding catheter (Codman Neurovascular,
Miami Lakes, FL, USA) was advanced to the cervical
portion of the involved IA or the vertebral artery, via
the right femoral artery. A Prowler select plus
microcatheter (Codman Neurovascular) was manipu-
lated over an Agility 0.010 microwire (Codman
Neurovascular) to the occlusion segment, confirming
the proximal and distal ends of the occluded IA to
measure the length of the occlusion segment. In the
case of IAT with thrombolytic, 100,000-200,000 units
of intra-arterial UK were infused directly into the
thrombus via this microcatheter and aggressive
mechanical thrombolysis (MT) was performed simulta-
neously with repeated penetration of the microcatheter
and microwire across the thrombus [19]. After verify-
ing lack of success in achieving recanalization for 10-
20 minutes, an intracranial self-expandable stent
(Enterprise vascular reconstruction device; Codman
Neurovascular) with double the length of the occlusion
segment was delivered across the occlusion segment
via the former microcatheter (Prowler select plus
microcatheter). After the utmost length of the retriev-
able stent was partially deployed across the occluded
segment, control angiography was performed to
confirm immediate recanalization of the occluded IA
and the second microcatheter (Prowler 14
microcatheter; Codman Neurovascular or SL-10
microcatheter; Boston Scientific, USA) was advanced
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into the proximal end of the occluded IA. An additional
100,000 units of UK and/or tirofiban (less than 1.5 mg)
were infused intra-arterially through the second
microcatheter in order to dissolve the residual thrombus
or prevent formation of an acute in-stent thrombus. A
delayed angiography after 30 minutes was performed to
maintain recanalization of the temporary stented IA
and the stent was resheathed and retrieved carefully. A
postprocedural angiography was also done to validate
recanalization. If reocclusion of the recanalized IA was
shown on the angiography, the second trial of TEB was
performed in the reoccluded IA. This procedure was
repeated several times until recanalization was
obtained. Control angiography was performed to
evaluate recanalization of the IA immediately after all
procedures. A closure device (Angio-seal; St. Jude
medical, St. Paul, MN, USA) was used in all patients
for hemostasis at the femoral artery puncture site.
Clinical Evaluation
The feasibility of TEB was evaluated by angiographic
result of recanalization. The initial and postprocedural
angiographies were compared by two neuroradiologists.
The status of vessel recanalization was evaluated
according to the Thrombolysis in Cerebral Ischemia
(TICI) scale[20, 21] (grade 0, no perfusion; grade I,
penetration but not perfusion; grade IIa, partial
perfusion with incomplete distal filling of < 50% of the
expected territory; grade IIb, partial perfusion with
incomplete distal filling of 50-99% of the expected
territory; grade IIc, near complete perfusion but with
delay in contrast runoff; grade III, full perfusion with
normal filling of distal branches in a normal hemody-
namic fashion) and recanalization after procedure was
defined as TICI grades II or III. 
The safety of this procedure was evaluated by
presence of procedure-related complications, such as
vessel dissection/perforation, inguinal hematoma, and
postprocedural hemorrhagic event (ICH), either
symptomatic (defined as worsening more than 4 points
of NIHSS score) or asymptomatic neurologic deteriora-
tion. 
Clinical outcome was evaluated by the NIHSS score
at discharge and the modif ied Rankin scale (mRS)
score at 3-month, which was determined by a neurolo-
gist (KYL). A CT was taken 1 day after the procedure
for evaluation of ICH and a brain MRI and MR
Angiography were performed after 7 days to evaluate
the patency of the recanalized vessel and extent of the
infarction. 
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Table1. Patients’ characteristics using TEB technique
No Sex Age Location Associated tPA Time to Time to Initial IAT Enterprise
Disease (mg/kg) Tx* Recan� Tx (drug) Stent (mm) Tx
1 M 69 MCA 0.9 250 300 MT UK, tirofiban 28 TEB
2� M 69 MCA AF/ 0.9 210 360 MT UK, tirofiban 28 TEB/
CA stenosis CA stenting
3 M 65 dIO AF none 220 360 MT UK, tirofiban 37 TEB
4� F 74 BA AF none 300 360 MT UK, tirofiban 28 TEB
5 M 58 MCA malignancy none 290 420 none tirofiban 28 TEB
6 M 55 dIO none 345 450 none tirofiban 37 TEB
7 M 50 MCA none 250 420 MT UK, tirofiban 28 TEB
8 F 72 dIO AF 0.9 180 360 MT UK, tirofiban 28 TEB
9 F 60 MCA malignancy 0.9 180 300 MT UK, tirofiban 28 TEB
10 M 54 MCA AF none 124 300 MT UK, tirofiban 28 TEB
11 M 50 MCA none 200 300 MT UK, tirofiban 28 TEB
Abbreviations: No, number; M, male; F, female; MCA, middle cerebral artery; BA, basilar artery; dIO, distal intracranial artery occlusion;
tPA, tissue plasminogen activator; Tx, treatment; MT, mechanical thrombolysis; IAT, intraarterial thrombolysis; UK, urokinase; ICH,
intracranial hemorrhage; NA, not available; AF, atrial fibrillation; CA, carotid artery; TEB, temporary endovascular bypass
* = time from onset to treatment (minutes)
�
= time to recanalization (minutes);
�
= previously reported cases [20, 21]
RESULTS
Eleven patients (8 men and 3 women, mean age 61.6
±9 years, range 50 to 74) were enrolled in this study
from January 2009 to May 2010 (Table 1). The mean
NIHSS score at admission was 12.8±4.3 (median 12).
All involved vessels presented with TICI 0 and the
occluded vessels were the middle cerebral artery (n=7),
the basilar artery (n=1), and the distal ICA occlusion
(n=3). A brain MRI (n=6) or brain computed tomogra-
phy angiography (n=10) was performed before
procedure [5]. patients had either a previous history of
atrial fibrillation or confirmed by ECG on admission
and two patients had gastrointestinal malignancies with
chemotherapy. Intravenous (IV) tPA (the dose 0.9
mg/kg) was infused in four patients and mechanical
thrombolysis with intra-arterial urokinase was
performed in nine. TEB was applied as a primary
treatment tool in two patients, who had bleeding
tendency with malignancy or arrived at hospital just
before the golden time of six hours. Intra-arterial
tirofiban (less than 1.5 mg) was administered in all
patients. One patient with MCA occlusion (patient 2)
had concomitant carotid artery stenosis and a stent was
placed in the proximal carotid artery before the
thrombolytic procedure. Recanalization using TEB was
achieved in 8 patients (73%); 8 (73 %) had TICI 2 or 3
and 3 had TICI 1(Table 2). There was no periproce-
dural complication in 11 patients. Mean duration from
onset to treatment start time was 235±66 minutes
(median 235 minutes, range 124-340 minutes) and
mean time from puncture to vessel recanalization was
123±49 minutes (median, 135 minutes; range 50 to
180 minutes). The average frequency of pass attempt
was 2.8±0.8 times (median 3times, range 2 to 4
times).  6 patients (55%) improved after the procedure
by more than 4 NIHSS points during hospitalization.
No patients had symptomatic ICH or worsened
neurologic examination; but 5 patients showed no
improvement in NIHSS of > 4 points. Two patients
(18%) had asymptomatic ICH. A follow-up brain MRI
showed preservation of the recanalized vessel 7 days
after thrombolysis in 8 patients (73%). The mean
NIHSS score at discharge was 6.2±3.8 (median, 6;
range 0 to 12). At the 3-month follow-up, mRS of ≤ 2
in 6 patients (55%). No ischemic event or progression
of neurological deficit occurred during follow-up. The
mortality rate was 9% (1/11; patient 8); After failure of
intraarterial(IA) thrombolysis with UK, TEB was
repeated 3 times until the golden time of 6 hours but
the MCA was not recanalized in the end.
DISCUSSION
In acute ischemic stroke, rapid recanalization is
strongly correlated with good clinical outcome and
reduced mortality [22]. While previously published
data about recanalization using IAT with thrombolytic
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Table 2. Clinical Outcome and Follow-up Results after TEB Technique
No. iNIHSS Initial TICI postTx TICI F/U NIHSS mRS(90D) AsICH
1 18 0 3 4 2 -
2* 17 0 3 4 1 Yes
3 13 0 2 4 1 -
4* 10 0 2 0 0 -
5 13 0 1 11 3 -
6 10 0 2 9 3 -
7 8 0 2 6 3 -
8 20 0 1 deceased 6 -
9 10 0 2 6 0 -
10 11 0 2 6 2 Yes
11 10 0 1 12 4 -
Abbreviations: TICI, thrombolysis in cerebral infarction; iNIHSS, initial NIHSS; F/U, Follow Up; postTx, post-treatment; AsICH, asympto-
matic intracranial hemorrhage
* = previously reported cases [20, 21]
(66%), MT with Merci device (69% in TIMI II/III) or
the Penumbra system (more than 80%) showed low
functional outcome (mRS ≤2 at 90-day ; 28 ~40%),
recanalization with stent implantation has recently
emerged as a new alternative method, which
demonstrates better results for recanalization (79 ~
100%) and clinical outcome in the treatment of the
acute ischemic stroke [1, 3, 4, 6, 23-25]. Although the
latter is fairly attractive in terms of rapid recanalization,
it has some drawbacks in practice. Particularly, it is a
burden to the clinicians that dual antiplatelet regimens
need to be administered after stent implantation despite
the risk of ICH and that regular follow up is mandatory
to avoid delayed complications, such as in-stent
restenosis/ thrombosis. Recently several authors
reported excellent recanalization (more than 90%) and
functional outcome (30-100%) was achieved in acute
ischemic stroke using mechanical thrombectomy with
full-retrievable stent [12-18].
Our study demonstrated that 8 of 11 (73%) patients
treated by TEB achieved recanalization of TICI grade 2
or 3 after adjunctive therapy. 6 patients (55%) showed
good clinical outcome (mRS≤2 at 90-day) and an
improvement of NIHSS≥4 in 6 patients(55%) at
discharge. These results showed a favorable procedural
and clinical outcome, although the other comparable
study using retrievable stents (Table 3) showed 88-
100% of recanalization rate and 30-100% of a good
functional outcome (mRS≤2 at 90-day) [12-18].
Remarkably, all occluded IAs showed immediate
recanalization (TICI ≥ 2) during TEB, and the
antegrade arterial flow was maintained with intra-
arterial infusion of tirofiban (mean dose 1.3±0.3 mg;
11 patients) or urokinase (less than 200,000 IU; 9
patients), which may accelerate thrombolysis endoge-
nously and pharmacologically with the thrombus
entrapped. In using the Enterprise stents, there was no
limitation of temporary stenting and immediate flow
restoration due to their various lengths from 14 to 37
mm, although the length of the thrombus is a limiting
factor in Solitaire stent study [18]. Furthermore mean
procedure time from puncture to recanalization was
123±49 minutes, and the average frequency of pass
attempt was 2.8±0.8 times in this study. This result
was also comparable with the previous MERCI study
but not superior to the result of the solitaire stent [3, 6,
12-18].
There was none of complication related with
procedure using the Enterprise stent. Procedure-related
complications were reported to occur in 6-10% of
recanalization procedures with stent implantation and
0% with the Solitaire stent [5, 13-18]. Since the
introduction of SES, it is possible to overcome vessel
tortuosity, the difficulties of navigation, and stiffness of
the device itself. Especially the Enterprise stent is
superior to other SESs in navigating tortuous cerebral
vessel [6, 7, 24, 27]. But it should be careful that
manipulation of the Enterprise stent in TEB may be
dangerous to dissection or vessel rupture because of its
own properties, such as partial deployment with the
flared stent ends, which had widened distally to more
than 7 mm, contrary to the Solitaire stent.
The symptomatic ICH rate was 0 % and the asympto-
matic ICH rate was 2 patients (18%), in whom recanal-
ization had achieved successfully and IV or intraarterial
thrombolytics and tirof iban were administered.
Hemorrhage may be induced by reperfusion injury after
recanalization or the administered medications. Actually
we used tirofiban combined with other f ibrinolytics
under the assumption that Use of tirof iban may be
necessary to maintain the microcirculation as well as the
reperfusion flow during the procedure and enhance the
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Table 3. Comparison of the Similar Studies Using Retrievable Stents
Authors N RR (%) iNIHSS mRS (≤ 2, %) sICH (%) Mortality (%)
Cohen et al [12] 6 100 22.1 100 0 0
Wehrschuetz et al [13] 11 100 16.1 30 0 9
Stampfl et al [14] 18 89 21 33.3 17 28
Miteff et al [15] 26 96 21.4 42.3 7.6 19
Park et al [16] 8 100 22.3 50 0 0
Roth et al [17] 22 91 19.4 50 9 18.1
Castano et al [18] 20 90 19 45 10 20
Our series 11 73 12.8 55 0 9
Abbreviations: N, number of patient; RR, recanalization rate; sICH, symptomatic ICH
fibrinolytic response. Although the risk of hemorrhage
associated with glycoprotein inhibitor and intraarterial/
IV fibrinolytics in acute stroke is controversial, it should
be kept in mind that tirofiban could raise the possibility
of hemorrhage and it could be a better way to choose
other treatment option, such as mechanical thrombec-
tomy using penumbra or solitaire stent. In terms of the
symptomatic ICH rate, this study presented a compara-
ble outcome to the similar studies using retrievable stent
(7-17%) [12-18] and other intra-arterial procedures,
such as the PROACT-II, MERCI and Penumbra pivotal
study (8-11%) [1, 25, 28].
In this study, recanalization was not achieved in three
patients. The causes of procedural failure were as
follows; 1) the possibilities of underlying arterial
stenosis according to the angiographic findings during
and after TEB, 2) a large amounts of the thrombus
burden, and 3) difficulty of resheathing the stent due to
tortuosity of the involved arteries. When the arteries
were occluded with underlying stenosis or an amount
of the thrombus burden, it is better to choose another
treatment option for the acute ischemic stroke.
Moreover, it may be dangerous to apply TEB technique
to the arterial occlusion with vascular tortuosity.
Although this SES had excellent navigability, stent
deployment and resheathing of the deployed stent are
distinct procedures. In retrieval of the Enterprise stent,
retrograde sheathing of the microcatheter should be
performed simultaneously without moving the half-
deployed stent in order to prevent intimal injury or
rupture of vessel. Therefore, stent implantation also
should be carefully considered as a substitute for
retrieval of the stent if performed in long-segmented
occlusion of the distal ICA, the underlying steno-
occlussive lesion and the tortuous vascular lesion.
There are some limitations to this study; 1) the
relatively small numbers of patients, 2) the retrospec-
tive evaluation of data collection and analysis, 3)
regional limitations of the device application (the
Penumbra system, MERCI device, Pharos intracranial
stent or solitaire stent) by the health insurance, 4) the
off-label use and the limited indication of the
Enterprise stent in recanalization of the acute IA
occlusion should be stressed and finally, we should
state that two of the patients in this study were
previously mentioned in an article describing
temporary recanalization in the treatment of acute
ischemic stroke [10, 11].
In conclusion, TEB may be a valuable treatment
option for the treatment of acute thromboembolic IA
occlusion without stent implantation. However this
technique should be carefully considered in case of the
suspicious steno-occlusive lesion, anatomical difficulty
and occlusion with a large thrombus burden.
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